Background

Recent work highlights the dangers of unregulated DIY CRISPR attempts and points to Life Biosciences' ER-100 trial as the first FDA‑approved study using viral vectors to deliver Yamanaka factors for optic nerve repair [1]. Although this approach shows promise, concerns remain about insertional mutagenesis, immune activation, and uncontrolled proliferation.

Hypothesis

We hypothesize that a transient, inducible expression system for the Yamanaka factors (OSKM) delivered via non‑integrating episomal vectors, preceded by a senolytic pretreatment (dasatinib + quercetin), will increase retinal ganglion cell (RGC) survival and axon regrowth after optic nerve injury without elevating tumorigenic markers compared to constitutive OSKM delivery alone.

Mechanistic Rationale

1. Episomal vectors (e.g., oriP/EBNA1‑based plasmids) replicate episomally and are diluted over cell divisions, limiting long‑term genomic integration and reducing insertional mutagenesis risk [2].
2. Inducible promoters (Tet‑On) allow precise temporal control; factors are expressed only during a defined therapeutic window, mimicking the transient reprogramming seen in regeneration‑competent species.
3. Senolytic pretreatment clears senescent retinal glial cells that secrete a pro‑inflammatory SASP, which otherwise inhibits axon growth and promotes a hostile microenvironment [3]. Removing these cells lowers oxidative stress and shifts microglia toward a pro‑repair phenotype.
4. Combined, these steps are expected to activate endogenous PGC‑1α‑mediated mitochondrial biogenesis, decreasing ROS and enhancing the metabolic support needed for axonal elongation, while the limited OSKM exposure reduces the chance of oncogenic transformation.

Experimental Design

• Model: Adult mice subjected to optic nerve crush (ONC).
• Groups (n=10 per group):
  1. Sham (injury only).
  2. Constitutive AAV‑OSKM (constant expression).
  3. Episomal inducible OSKM (no senolytic).
  4. Senolytic pretreatment (dasatinib + quercetin, 3 days) followed by episodic inducible OSKM.
  5. Senolytic pretreatment + vehicle (control for drug effects).
• Interventions: intravitreal injection of vectors; doxycycline administered via chow for 7 days post‑injury to induce OSKM.
• Readouts (at 2 weeks and 4 weeks post‑ONC):
  • RGC survival (Brn3a+ cell counts).
  • Axon regeneration distance past lesion site ( immunostained for GAP‑43).
  • Senescent glial burden (p16^INK4a^ staining).
  • Mitochondrial ROS (MitoSOX fluorescence).
  • Tumorigenic risk: serum circulating tumor DNA (ctDNA) levels and histopathological screening for hyperplasia.
• Statistical analysis: ANOVA with Tukey post‑hoc; significance set at p<0.05.

Predictions

• Group 4 (senolytic + episomal inducible OSKM) will show ≥30 % greater RGC survival and ≥2‑fold longer axon regrowth than Group 2 (constitutive AAV‑OSKM).
• Senescent glial burden and mitochondrial ROS will be significantly reduced in Group 4 versus Groups 2‑3.
• ctDNA levels and histopathological evidence of neoplasia will not differ between Group 4 and sham controls, falsifying a tumorigenic effect.

Potential Pitfalls & Mitigations

• Vector episomal loss in non‑dividing RGCs could reduce efficacy; mitigation includes using AAV‑derived episomal scaffolds that persist in neurons.
• Senolytic toxicity; we will monitor liver enzymes and weight to adjust dosage.
• Off‑target CRISPR concerns are avoided because no nucleases are employed.

If the data confirm enhanced regeneration without increased tumorigenic signals, this strategy would provide a safer, mechanistically grounded alternative to unregulated self‑experimentation and current viral‑vector approaches, advancing the translation of cellular reprogramming for retinal repair.